CONFERENCE COVERAGE 2011-07-29 Conference Coverage After disappointing trial results for Alzheimer’s disease (AD) drugs, all eyes are on the Phase 3 clinical trials of two monoclonal antibodies to amyloid-β: bapineuzumab, developed by Janssen Alzheimer Immunotherapy and Pfizer, and sol
PAPER Vercambre MN, Grodstein F, Manson JE, Stampfer MJ, Kang JH
Arch Intern Med. 2011 Jul 25;171(14):1244-50. PubMed: 21771894
PAPER Middleton LE, Manini TM, Simonsick EM, Harris TB, Barnes DE, Tylavsky F, Brach JS, Everhart JE, Yaffe K
Arch Intern Med. 2011 Jul 25;171(14):1251-7. PubMed: 21771893
CONFERENCE COVERAGE SERIES Paris: Renamed ARIA, Vasogenic Edema Common to Anti-Amyloid Therapy Paris: Semagacestat Autopsy and Other News of Trial Tribulations Paris: More Trial News, Mixed at Best Paris: President and All, French Science Takes the Stage Paris: Beyond Genomics, Fre